Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q3 2023 Earnings Call Transcript
Operator: Welcome to Acorda Therapeutics Third Quarter 2023 Financial and Business Update. At this time, all participants are in a listen-only mode.
Acorda Therapeutics Inc. (ACOR)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | 0 | $0 | 0% | ||
| 2. | Davidson Kempner Thomas Lenox Kempner | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | ||
| 4. | 0 | $0 | 0% | ||
| 5. | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $0.65 | 10,000 | $6,500.00 | 149,757 | 2023-03-17 | Filing | |
| $0.60 | 10,156 | $6,093.60 | 139,757 | 2023-03-16 | Filing | |
| $19.62 | 116,201 | $2,280,119.26 | 8,474,728 | 2017-08-29 | Filing | |
| $19.52 | 150,000 | $2,927,280.00 | 8,358,527 | 2017-08-29 | Filing | |
| $19.05 | 500,000 | $9,523,050.00 | 8,208,527 | 2017-08-29 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $1.70 | 2,289 | $3,894.50 | 129,601 | 2022-03-17 | Filing | |
| $1.60 | 2,227 | $3,552.73 | 117,420 | 2019-12-02 | Filing | |
| $1.60 | 1,513 | $2,421.10 | 12,624 | 2019-12-02 | Filing | |
| $1.60 | 1,176 | $1,879.95 | 12,961 | 2019-12-02 | Filing | |
| $1.60 | 4,699 | $7,505.24 | 607,287 | 2019-12-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% |
News See All
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q2 2023 Earnings Call Transcript
Operator: Welcome to Acorda Therapeutics Second Quarter 2023 Financial and Business Update. At this time, all participants are in a listen-only mode.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q1 2023 Earnings Call Transcript
Operator: Welcome to Acorda Therapeutics First Quarter 2023 Financial and Business Update. [Operator Instructions]. Please be advised that this call is being recorded at the company's request.
Acorda Therapeutics, Inc. (NASDAQ:ACOR) Q4 2022 Earnings Call Transcript
Operator: Welcome to the Acorda Therapeutics Fourth Quarter and Year-End 2022 Financial and Business Update. Please be advised that this call is being recorded at the company's request.
Hedge Funds Are Buying Acorda Therapeutics Inc (ACOR) Again
The Insider Monkey team has completed processing the quarterly 13F filings for the March quarter submitted by the hedge funds and other money managers included in our extensive database.
Is ACOR A Good Stock To Buy Now?
At the end of February we announced the arrival of the first US recession since 2009 and we predicted that the market will decline by at least 20% in (Recession is Imminent: We Need A Travel Ban NOW).
Do Hedge Funds Love Acorda Therapeutics Inc (ACOR)?
How do you pick the next stock to invest in? One way would be to spend days of research browsing through thousands of publicly traded companies.
Hedge Fund and Insider Trading News: Bill Ackman, Marshall Wace, Greenlight Capital, Becton Dickinson and Co (BDX), On Track Innovations Ltd (OTIVF), and More
COPENHAGEN (Reuters) - Hedge fund Marshall Wace is betting on Danske Bank (DANSKE.CO) shares falling after taking a short position in the Danish lender of 0.5% of issued shares, the Danish FSA said on...
Hedge Funds Are Getting Burned By Acorda Therapeutics Inc (ACOR)
After several tireless days we have finished crunching the numbers from nearly 750 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed...
Were Hedge Funds Right About Dumping Acorda Therapeutics Inc (ACOR)?
We are still in an overall bull market and many stocks that smart money investors were piling into surged through October 17th.
Billionaire Hedge Funds
